Cognitive Neurosciences collaborate with Baylor College of Medicine on groundbreaking OCD study

The company’s CognICA(TM) tool will be published in the pivotal Baylor College of Medicine study of the world’s largest ethnically diverse population with OCD.

Vancouver, British Columbia – (Newsfile Corp. – September 13, 2022) – Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) (“Company” or “Knowledge”)The technology company that has created a unique brain health screening platform for use in medical, commercial and consumer settings is pleased to announce that the Integrated Cognitive Assessment (“ICATechnology in the form of FDA-registered CognICATMto be published in a multicenter clinical study (“Stady“) conducted by the prestigious Baylor College of Medicine (“Baylorlocated in Houston, Texas. It aims to understand how genetic factors influence the risk of developing obsessive-compulsive disorder (“OCD”).Obsessive-compulsive disorder”) in Latin American individuals.

The study will use CognICATM The platform’s unique capabilities to help identify subtle differences in cognition in people with the disease to help Baylor researchers understand whether specific genetic variants are responsible for the most clinically significant symptoms and thus determine treatment goals. Obsessive-compulsive disorder and related disorders are of major public health importance due to their high personal and societal costs. OCD alone accounts for 5.7% of the total costs of mental illness1 It is expected to rise to $6 trillion by 20302. The study is being conducted across the USA and Latin America and will include 5,000 Latin American individuals, the largest and most ancestral sample of OCD cases in the world.

Dr. Eric Storch, chief researcher at Baylor, commented: “Overall, the study will improve our understanding of the causes of OCD, with the goal of improving patient life and decreasing the incidence and impact of this disease. Using CognICA’s powerful CognetivityTM The platform and its ability to measure cognitive function sensitively and frequently, regardless of language and cultural differences, gives researchers the exact tool they need to better understand how the cognitive performance of patients at different stages of OCD changes in a way that has hitherto been impossible. “

Cognetivity’s Chief Medical Officer, Dr. Chris Kalafatis, commented, “We are pleased to collaborate with Baylor College of Medicine on the world’s first investigation of the interaction between genes and clinical manifestations of obsessive-compulsive disorder. As we continue to commercialize CognICA.TM platform, these types of unique and very important deployments not only help demonstrate the unique capabilities of our platform for both clinical and research work, but also provide us with large amounts of high-quality data that can be used to fine-tune and add more to technology, thus expanding the range of new future applications and disguised. Dr. Kalafatis added, “The scope of our technology to help address this exponentially growing problem of mental health, and to make help available to as many people as possible is a huge part of our mission at Cognetivity.”

About Cognetivity Neurosciences Ltd.

Cognetivity is a technology company that has built a cognitive testing platform for use in medical, commercial, and consumer settings. Cognetivity’s Cognetivity uses artificial intelligence and machine learning techniques to help detect early signs of cognitive impairment by testing the performance of large areas of the brain. CognICA™ is currently available for clinical use in the USA, UK, Europe and UAE with regulatory approval for other regions planned for 2022.

About Baylor College of Medicine

Baylor College of Medicine ( in Houston is recognized as a University of the Health Sciences and is known for excellence in education, research, and patient care. Ranked 22second abbreviation Among medical schools for research and 17The tenth For primary care by US News & World Report. Baylor 20 . is listedThe tenthAmong all US medical schools to fund the National Institutes of Health and #1 in Texas. Baylor Pediatrics Program ranked 7The tenth Of all the pediatric programs, reflecting the strong association with Texas Children’s Hospital where our faculty cares for pediatric patients and trains our students and residents. Nationally, our Physician Assistant Program is ranked 3rdresearch and development In the category of health specialties, the Anesthesia Program for Nurses ranked secondsecond abbreviation. Located in the Texas Medical Center, Baylor has affiliations with seven teaching hospitals and jointly owns and operates Baylor St. Luke’s Medical Center, part of St. Luke’s Health. Currently, Baylor has more than 3,000 interns in medical anesthesiology, graduate, nurse, physician assistant, orthopedic, genetic counseling as well as residents and postdoctoral fellows. Follow Baylor College of Medicine on Facebook ( and twitter (

For more information, please visit the website: Or contact:
For media inquiries, please contact: Josh Stanbury | | 416-628-7441

On behalf of the Council

“Sina my love”
Sina my love
CEO and Director

Forward-looking statements:

Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “expect”, “assume”, “believe”, “plan”, “estimate”, “expects,” “intends,” “may,” “should,” and similar expressions to the extent they relate to the Company or its management. Forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This news release contains forward-looking statements. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. These statements are based on current expectations, estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. This data and information is based on several assumptions regarding current and future business strategies and the environment in which the company will operate in the future. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Readers should not place undue reliance on the company’s forward-looking statements.

The Canadian Stock Exchange is not responsible for the adequacy or accuracy of this release.


1 DuPont RL, Rice DB, Shiraki S, Roland CR. The economic costs of obsessive-compulsive disorder. Interface Med 1995; 8: 102-9

2 Lancet Global Health Volume 8, version 11E1352, November 1, 2020

To view the source version of this press release, please visit

Leave a Comment